se of Platelet-enriched allogeneic serum eye drops as an adjuvant for the treatment of recurrent Ligneous conjunctivitis

niversidade Federal de São Paulo - UNIFESP/EPM0 个研究点开始时间: 2024年4月29日最近更新: 2024年5月27日

试验速览

暂无简介。

•Patients diagnosed with ligneous conjunctivitis with chronic ocular involvement (more than 1 year of disease) who do not respond to clinical treatment and present recurrence of pseudomembranes after simple resection or after attempted clinical treatment. Age from 2 years. Availability to attend all study visits and adequately follow all post-operative guidelines and care. Understanding of the study, stages and follow-up, and agreement expressed by signing the consent form (by the patient or guardian) and assent form (when applicable). Stable clinical condition and no change in topical medications or systemic anti-inflammatory drugs in the 60 days prior to and during the study. Carry out a complete pre-operative assessment, including general and specific complementary exams as clinically indicated and pre-anesthetic assessment

•Eye surgery in the last 6 months. Patients with a previous history of hypersensitivity to any of the products used to treat ligneous conjunctivitis included in this protocol. Pregnant or breastfeeding women. Active eye infection. History of herpetic keratitis. Use of contact lenses within 48 hours of the start of the study, or during the study. Glaucoma. Presence of any other serious ocular change that indicates the need to perform another ophthalmological procedure more urgently, such as retinal detachment or ocular perforation. Contraindication to carrying out the procedure by the anesthesiology team

发起方

niversidade Federal de São Paulo - UNIFESP/EPM